TEST:

Strata Select™

Strata Select is a pan-solid tumor molecular profiling test for patients with advanced cancer that provides treatment selection guidance for immunotherapy and beyond. It identifies ~8% of patients currently not indicated for anti-PD-(L)1 monotherapy who are predicted to benefit; ~20% of currently treated patients who could be spared ineffective treatment and risk of side effects; ~35% of currently treated patients who can consider anti-PD-(L)1 monotherapy and be spared unnecessary combination chemotherapy.